Cephalon, Inc. Case Solution
In early 1997, Cephalon, awaited an FDA panel's conclusion on whether its drug, Myotrophin, would be approved. If the drug was approved, the firm might want considerable additional funds to commercialize and to purchase the rights again.
The CFO of the firm is contemplating various funding strategies, including paying for those options by issuing shares at the present time and purchasing call options on the firm's own stock.
This is just an excerpt. This case is about FINANCE & ACCOUNTING
PUBLICATION DATE: April 13, 1998
Related Case Solutions & Analyses:
Factory 539: China Star Technology Electronics Ltd. B
Retiree Pension and Health Benefits
Lundberg Systems: 3 Vignettes
Accounting for Asset-Backed Securitization
Ancient Fable
W. K. Kellogg Company A
Taxing Situations: Two Cases on Income Taxes and Financial Reporting
Panera Bread Company
Polanco: A Fashionable Opportunity
Kmart, Inc. and Builders Square
